Posted by Michael Wonder on 12 Mar 2024
Updated agenda for March 2024 PBAC meeting (12 March 2024)
12 March 2024 - There are five late changes to the agenda for this week's PBAC meeting.
- Ravulizumab (Ultomiris) - To be considered at a future PBAC meeting
- Cytosine arabinoside with daunorubicin (nanoparticle, liposomal) (Vyxeos) - withdrawn
- Venetoclax (Venclexta) - withdrawn
- Aflibercept (Eylea) - To be considered at a future PBAC meeting
- Aflibercept (Eylea) - To be considered at a future PBAC meeting
